Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis

Abstract Background Each year 25 000–32 000 children develop rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB), and many more require preventive treatment. Levofloxacin is a key component of RR/MDR-TB treatment and prevention, but the existing pharmacokinetic data in children have not yet...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinical infectious diseases Ročník 78; číslo 3; s. 756 - 764
Hlavní autoři: White, Yasmine N, Solans, Belen P, Denti, Paolo, van der Laan, Louvina E, Schaaf, H Simon, Vonasek, Bryan, Malik, Amyn A, Draper, Heather R, Hussain, Hamidah, Hesseling, Anneke C, Garcia-Prats, Anthony J, Savic, Radojka M
Médium: Journal Article
Jazyk:angličtina
Vydáno: US Oxford University Press 20.03.2024
Témata:
Adult
Antitubercular Agents
Child
Humans
Infant
Infant, Newborn
Levofloxacin
Rifampin - pharmacokinetics
Rifampin - therapeutic use
Tablets - therapeutic use
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - prevention & control
pharmacokinetics
levofloxacin
drug-resistant tuberculosis
pediatrics
ISSN:1058-4838, 1537-6591, 1537-6591
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Abstract Background Each year 25 000–32 000 children develop rifampicin- or multidrug-resistant tuberculosis (RR/MDR-TB), and many more require preventive treatment. Levofloxacin is a key component of RR/MDR-TB treatment and prevention, but the existing pharmacokinetic data in children have not yet been comprehensively summarized. We aimed to characterize levofloxacin pharmacokinetics through an individual patient data meta-analysis of available studies and to determine optimal dosing in children. Methods Levofloxacin concentration and demographic data were pooled from 5 studies and analyzed using nonlinear mixed effects modeling. Simulations were performed using current World Health Organization (WHO)–recommended and model-informed optimized doses. Optimal levofloxacin doses were identified to target median adult area under the time-concentration curve (AUC)24 of 101 mg·h/L given current standard adult doses. Results Data from 242 children (2.8 years [0.2–16.8] was used). Apparent clearance was 3.16 L/h for a 13-kg child. Age affected clearance, reaching 50% maturation at birth and 90% maturation at 8 months. Nondispersible tablets had 29% lower apparent oral bioavailability compared to dispersible tablets. Median exposures at current WHO-recommended doses were below the AUC target for children weighing <24 kg and under <10 years, resulting in approximately half of the exposure in adults. Model-informed doses of 16–33 mg/kg for dispersible tablets or 16–50 mg/kg for nondispersible tablets were required to meet the AUC target without significantly exceeding the median adult Cmax. Conclusions Revised weight-band dosing guidelines with doses of >20 mg/kg are required to ensure adequate exposure. Further studies are needed to determine safety and tolerability of these higher doses. Most children receiving levofloxacin for the treatment or prevention of rifampicin- and multidrug-resistant tuberculosis at currently recommended doses will not achieve adult-matched exposures. New guidelines with increased levofloxacin doses for children weighing <24 kg are proposed to ensure adequate exposure.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciae024